{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:05:38Z","timestamp":1793837138126,"version":"4.6.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2025M772209"],"award-info":[{"award-number":["2025M772209"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373358"],"award-info":[{"award-number":["82373358"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003395","name":"Shanghai Municipal Education Commission","doi-asserted-by":"publisher","award":["2023ZKZD23"],"award-info":[{"award-number":["2023ZKZD23"]}],"id":[{"id":"10.13039\/501100003395","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"DOI":"10.1038\/s43856-026-01444-6","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T04:54:52Z","timestamp":1771304092000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Distinct prognostic value of [18F]FDG PET and [68Ga]Ga-PSMA-11 PET in advanced hormone-sensitive prostate cancer"],"prefix":"10.1038","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7578-1911","authenticated-orcid":false,"given":"Ang","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haotian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinjie","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linglin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayan","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruopeng","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2044-9238","authenticated-orcid":false,"given":"Qi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahua","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0124-9433","authenticated-orcid":false,"given":"Wei","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"key":"1444_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer statistics, 2024. CA Cancer J. Clin. 74, 12\u201349 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"1444_CR2","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"1444_CR3","doi-asserted-by":"publisher","first-page":"288","DOI":"10.5534\/wjmh.180040","volume":"37","author":"K Fujita","year":"2019","unstructured":"Fujita, K. & Nonomura, N. Role of androgen receptor in prostate cancer: a review. World J. Mens. Health 37, 288\u2013295 (2019).","journal-title":"World J. Mens. Health"},{"key":"1444_CR4","doi-asserted-by":"publisher","first-page":"3584","DOI":"10.1200\/JCO.23.00723","volume":"41","author":"J Wala","year":"2023","unstructured":"Wala, J., Nguyen, P. & Pomerantz, M. Early treatment intensification in metastatic hormone-sensitive prostate cancer. J. Clin. Oncol. 41, 3584\u20133590 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1444_CR5","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1056\/NEJMe1704992","volume":"377","author":"CJ Logothetis","year":"2017","unstructured":"Logothetis, C. J. Improved outcomes in men with advanced prostate cancer. N. Engl. J. Med. 377, 388\u2013390 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1444_CR6","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","volume":"377","author":"K Fizazi","year":"2017","unstructured":"Fizazi, K. et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N. Engl. J. Med. 377, 352\u2013360 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1444_CR7","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1056\/NEJMe1905891","volume":"381","author":"L Klotz","year":"2019","unstructured":"Klotz, L. Apalutamide for metastatic, hormone-responsive prostate cancer. N. Engl. J. Med. 381, 84\u201386 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1444_CR8","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s11912-017-0568-7","volume":"19","author":"M Nakazawa","year":"2017","unstructured":"Nakazawa, M., Paller, C. & Kyprianou, N. Mechanisms of therapeutic resistance in prostate cancer. Curr. Oncol. Rep. 19, 13 (2017).","journal-title":"Curr. Oncol. Rep."},{"key":"1444_CR9","doi-asserted-by":"publisher","unstructured":"Heesterman B. L. et al. Increased incidence of primary metastatic prostate cancer in the era of PSMA PET\/CT: a population-based analysis. Eur. J. Nucl. Med. Mol. Imaging https:\/\/doi.org\/10.1007\/s00259-025-07431-8 (2025).","DOI":"10.1007\/s00259-025-07431-8"},{"key":"1444_CR10","doi-asserted-by":"publisher","first-page":"115966","DOI":"10.1016\/j.ejmech.2023.115966","volume":"263","author":"G Capasso","year":"2024","unstructured":"Capasso, G., Stefanucci, A. & Tolomeo, A. A systematic review on the current status of PSMA-targeted imaging and radioligand therapy. Eur. J. Med. Chem. 263, 115966 (2024).","journal-title":"Eur. J. Med. Chem."},{"key":"1444_CR11","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13550-025-01265-z","volume":"15","author":"MJ Roberts","year":"2025","unstructured":"Roberts, M. J. et al. A prospective, multi-centre trial of PSMA-PET compared to FDG-PET for staging of newly diagnosed high risk prostate cancer. EJNMMI Res. 15, 92 (2025).","journal-title":"EJNMMI Res."},{"key":"1444_CR12","doi-asserted-by":"publisher","first-page":"6082","DOI":"10.7150\/thno.44584","volume":"10","author":"DA Ferraro","year":"2020","unstructured":"Ferraro, D. A. et al. Immunohistochemical PSMA expression patterns of primary prostate cancer tissue are associated with the detection rate of biochemical recurrence with 68Ga-PSMA-11-PET. Theranostics 10, 6082\u20136094 (2020).","journal-title":"Theranostics"},{"key":"1444_CR13","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s00259-023-06392-0","volume":"51","author":"F Gossili","year":"2023","unstructured":"Gossili, F. et al. The diagnostic accuracy of radiolabeled PSMA-ligand PET for tumour staging in newly diagnosed prostate cancer patients compared to histopathology: a systematic review and meta-analysis. Eur. J. Nucl. Med. Mol. Imaging 51, 281\u2013294 (2023).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1444_CR14","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1007\/s00259-022-06089-w","volume":"50","author":"WP Fendler","year":"2023","unstructured":"Fendler, W. P. et al. PSMA PET\/CT: joint EANM procedure guideline\/SNMMI procedure standard for prostate cancer imaging 2.0. Eur. J. Nucl. Med. Mol. Imaging 50, 1466\u20131486 (2023).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1444_CR15","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","volume":"86","author":"Cornford","year":"2024","unstructured":"Cornford et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer\u20142024 Update. Part I: screening, diagnosis, and local treatment with curative intent. Eur. Urol. Elsevier 86, 148\u2013163 (2024).","journal-title":"Eur. Urol. Elsevier"},{"key":"1444_CR16","doi-asserted-by":"publisher","first-page":"924","DOI":"10.3390\/medicina61050924","volume":"61","author":"J G\u00f3mez Rivas","year":"2025","unstructured":"G\u00f3mez Rivas, J. et al. Prostate-specific membrane antigen positron emission tomography (PSMA-PET) in initial staging of prostate cancer patients: the beginning of a new era. Medicina 61, 924 (2025).","journal-title":"Medicina"},{"key":"1444_CR17","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s12253-008-9104-2","volume":"15","author":"S Mannweiler","year":"2009","unstructured":"Mannweiler, S. et al. Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis. Pathol. Oncol. Res. 15, 167\u2013172 (2009).","journal-title":"Pathol. Oncol. Res."},{"key":"1444_CR18","doi-asserted-by":"publisher","first-page":"23902","DOI":"10.1038\/s41598-025-06393-z","volume":"15","author":"Y Mulati","year":"2025","unstructured":"Mulati, Y. et al. Characterizing PSMA heterogeneity in prostate cancer and identifying clinically actionable tumor associated antigens in PSMA negative cases. Sci. Rep. 15, 23902 (2025).","journal-title":"Sci. Rep."},{"key":"1444_CR19","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41585-024-00900-z","volume":"22","author":"MK Bakht","year":"2025","unstructured":"Bakht, M. K. & Beltran, H. Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer. Nat. Rev. Urol. 22, 26\u201345 (2025).","journal-title":"Nat. Rev. Urol."},{"key":"1444_CR20","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s12032-020-01412-7","volume":"37","author":"L Dong","year":"2020","unstructured":"Dong, L. et al. Prospective evaluation of 68Ga-PSMA-11 PET\/CT in Chinese men with biochemical recurrence after radical prostatectomy for prostate cancer: relationships between location of recurrence, time after prostatectomy, and serum PSA level. Med. Oncol. 37, 89 (2020).","journal-title":"Med. Oncol."},{"key":"1444_CR21","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.eururo.2024.09.005","volume":"86","author":"AB Weiner","year":"2024","unstructured":"Weiner, A. B. et al. Molecular hallmarks of prostate-specific membrane antigen in treatment-na\u00efve prostate cancer. Eur. Urol. 86, 579\u2013587 (2024).","journal-title":"Eur. Urol."},{"key":"1444_CR22","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s11307-021-01605-0","volume":"23","author":"J Roy","year":"2021","unstructured":"Roy, J. et al. Monitoring PSMA responses to ADT in prostate cancer patient-derived xenograft mouse models using [18F]DCFPyL PET imaging. Mol. Imaging Biol. 23, 745\u2013755 (2021).","journal-title":"Mol. Imaging Biol."},{"key":"1444_CR23","doi-asserted-by":"publisher","first-page":"2411017","DOI":"10.1080\/07853890.2024.2411017","volume":"56","author":"A Li","year":"2024","unstructured":"Li, A. et al. Prognostic value of [18F]FDG PET\/CT in metastatic hormone-sensitive prostate cancer at initial diagnosis: a retrospective cohort study. Ann. Med 56, 2411017 (2024).","journal-title":"Ann. Med"},{"key":"1444_CR24","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1038\/s41391-021-00391-8","volume":"24","author":"M Bauckneht","year":"2021","unstructured":"Bauckneht, M. et al. The prognostic power of 18F-FDG PET\/CT extends to estimating systemic treatment response duration in metastatic castration-resistant prostate cancer (mCRPC) patients. Prostate Cancer Prostatic Dis. Nat. Publ. Group 24, 1198\u20131207 (2021).","journal-title":"Prostate Cancer Prostatic Dis. Nat. Publ. Group"},{"key":"1444_CR25","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.2967\/jnumed.118.223263","volume":"60","author":"H Jadvar","year":"2019","unstructured":"Jadvar, H. et al. Prediction of time to hormonal treatment failure in metastatic castration-sensitive prostate cancer with 18F-FDG PET\/CT. J. Nucl. Med. 60, 1524\u20131530 (2019).","journal-title":"J. Nucl. Med."},{"key":"1444_CR26","doi-asserted-by":"publisher","first-page":"1607227","DOI":"10.3389\/fmed.2025.1607227","volume":"12","author":"CM Iacovitti","year":"2025","unstructured":"Iacovitti, C. M. et al. Diagnostic value of dual-tracer PET\/CT with [18F]FDG and PSMA ligands in prostate cancer: an updated systematic review. Front. Med. 12, 1607227 (2025).","journal-title":"Front. Med."},{"key":"1444_CR27","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/RLU.0000000000005587","volume":"50","author":"L Bian","year":"2025","unstructured":"Bian, L. et al. Dual-Tracer 18 F-FDG and 68 Ga-PSMA PET\/CT Imaging of Heterogeneous Phenotypes of Metastatic Castration-Resistant Prostate Cancer for Predicting Response to Novel Hormone Therapy. Clin. Nucl. Med 50, 143\u2013149 (2025).","journal-title":"Clin. Nucl. Med"},{"key":"1444_CR28","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1007\/s00259-023-06585-7","volume":"51","author":"J Kim","year":"2024","unstructured":"Kim, J. et al. Combination of [18F]FDG and [18F]PSMA-1007 PET\/CT predicts tumour aggressiveness at staging and biochemical failure postoperatively in patients with prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 51, 1763\u20131772 (2024).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1444_CR29","doi-asserted-by":"publisher","first-page":"3652","DOI":"10.1200\/JCO.23.00155","volume":"41","author":"KS Virgo","year":"2023","unstructured":"Virgo, K. S., Rumble, R. B. & Talcott, J. Initial management of noncastrate advanced, recurrent, or metastatic prostate cancer: ASCO guideline update. J. Clin. Oncol. 41, 3652\u20133656 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1444_CR30","doi-asserted-by":"publisher","first-page":"469","DOI":"10.6004\/jnccn.2025.0052","volume":"23","author":"DE Spratt","year":"2025","unstructured":"Spratt, D. E. et al. Prostate Cancer, Version 3.2026, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Canc Netw. 23, 469\u2013493 (2025).","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"1444_CR31","doi-asserted-by":"publisher","unstructured":"Hi S. et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working Group 3. Journal of clinical oncology: official journal of the American Society of Clinical Oncology [Internet]. J Clin Oncol; 2016 [cited 2025 Nov 18];34. https:\/\/doi.org\/10.1200\/JCO.2015.64.2702","DOI":"10.1200\/JCO.2015.64.2702"},{"key":"1444_CR32","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"1444_CR33","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1007\/s00259-016-3439-9","volume":"43","author":"SM Schwarzenb\u00f6ck","year":"2016","unstructured":"Schwarzenb\u00f6ck, S. M. et al. Prospective evaluation of [11C]Choline PET\/CT in therapy response assessment of standardized docetaxel first-line chemotherapy in patients with advanced castration refractory prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 43, 2105\u20132113 (2016).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1444_CR34","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1097\/RLU.0000000000000313","volume":"39","author":"G Cheng","year":"2014","unstructured":"Cheng, G., Alavi, A., Werner, T. J., Del Bello, C. V. & Akers, S. R. Serial changes of FDG uptake and diagnosis of suspected lung malignancy: a lesion-based analysis. Clin. Nucl. Med. 39, 147\u2013155 (2014).","journal-title":"Clin. Nucl. Med."},{"key":"1444_CR35","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1007\/s12149-014-0900-3","volume":"28","author":"K Kubota","year":"2014","unstructured":"Kubota, K. et al. Lesion-based analysis of 18F-FDG uptake and 111In-Pentetreotide uptake by neuroendocrine tumors. Ann. Nucl. Med 28, 1004\u20131010 (2014).","journal-title":"Ann. Nucl. Med"},{"key":"1444_CR36","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1007\/s12094-024-03625-y","volume":"27","author":"I Henr\u00edquez","year":"2025","unstructured":"Henr\u00edquez, I. et al. PSMA PET\/CT SUVmax as a prognostic biomarker in patients with metachronous metastatic hormone-sensitive prostate cancer (mHSPC). Clin. Transl. Oncol. 27, 706\u2013715 (2025).","journal-title":"Clin. Transl. Oncol."},{"key":"1444_CR37","doi-asserted-by":"publisher","unstructured":"Marchetti, A. et al. The prognostic role of 68GA-PSMA-PET\/CT in metastatic hormone-sensitive prostate cancer: a preliminary analysis. Clinical Genitourinary Cancer [Internet]. Elsevier; 2025 [cited 2025 Aug 2];0. https:\/\/doi.org\/10.1016\/j.clgc.2025.102406","DOI":"10.1016\/j.clgc.2025.102406"},{"key":"1444_CR38","doi-asserted-by":"publisher","first-page":"8971","DOI":"10.1038\/ncomms9971","volume":"6","author":"D Aran","year":"2015","unstructured":"Aran, D., Sirota, M. & Butte, A. J. Systematic pan-cancer analysis of tumour purity. Nat. Commun. Nat. Publ. Group 6, 8971 (2015).","journal-title":"Nat. Commun. Nat. Publ. Group"},{"key":"1444_CR39","doi-asserted-by":"publisher","first-page":"100399","DOI":"10.1016\/j.patter.2021.100399","volume":"3","author":"MU Oner","year":"2022","unstructured":"Oner, M. U. et al. Obtaining spatially resolved tumor purity maps using deep multiple instance learning in a pan-cancer study. Patterns 3, 100399 (2022).","journal-title":"Patterns"}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01444-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01444-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01444-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T14:31:41Z","timestamp":1774535501000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01444-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1444"],"URL":"https:\/\/doi.org\/10.1038\/s43856-026-01444-6","relation":{},"ISSN":["2730-664X"],"issn-type":[{"value":"2730-664X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,17]]},"assertion":[{"value":"27 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"164"}}